It is well-established that syngeneic mouse models represent a powerful tool to evaluate therapies that target the immune system. The key to understanding your immuno-modulatory compound’s efficacy is to work with well-characterised models, with known growth kinetics and/or response to standard of care treatments.

At InnoSer, we are experienced with validating our clients’ cell lines to help determine the optimal seeding cell densities to induce stable and progressive in vivo tumour growth.

Our immuno-oncology teams have validated multiple commonly available cell lines such as metastatic breast cancer (4T1), pancreatic (Panc02), melanoma (B16F10) renal (Renca) and colorectal (MC38) carcinoma.

MC38 represents a common anti-PD-1-responsive tumour model. Disease progression is assessed via observation of clinical signs, body weight and tumour volume measurements. This model shows efficient growth kinetics and response to anti-PD-1 therapy (Left figure shows tumour volume measured by callipers, M ± SEM, **P<0.01, ***P<0.001) resulting in a model with a long dosing window to test novel immunotherapy candidates. InnoSer offers this both as a subcutaneous (MC38) and orthotopic (MC38-luc) model allowing bioluminescent imaging of tumour progression (Right image shows tumour progression in a subset of two mice).

Evaluating novel immunotherapies’ mechanisms of action can be complemented with extensive immune cell profiling, with custom-tailored panel establishment upon request.

Here, we performed immune cell profiling on colorectal carcinoma (MC38) tumours isolated from anti-PD-1 treated and vehicle-treated mice. Using panels for (A) myeloid cells and (B) lymphocyte cells, different cell populations can be distinguished including T cells (CD4+ vs. CD8+), B cells, monocytes, granulocytes and M1/M2 macrophages.  

Alternatively, tumour growth assessment can be also performed following subcutaneous flank injections of novel cell-based therapy products to monitor tumorigenicity as a side effect.  

To help you fine-tune your lead compound’s bioavailability, InnoSer has ample experience in carrying out PK/PD studies and analyses. To ensure your compound’s safety, InnoSer can additionally perform safety pharmacology analyses.

Be the first to know – get this news straight to your inbox

InnoSer provides a variety of validated in vitro and in vivo screening tests for immunology and oncology. If you require additional information, feel free to reach out, and we will respond within a few days.

We provide a monthly update from our oncology labs containing scientific insights into our research services. To get news straight to your inbox please sign up here.

Related Resources

Compare our model capabilities and discover which of our oncology platforms suits your research needs

Download our oncology models data leaflet

Oncology research models and services overview page